Revvity, Inc. (RVTY)

Market Cap	11.61B
Revenue (ttm)	2.77B
Net Income (ttm)	286.61M
Shares Out	117.87M
EPS (ttm)	2.35
PE Ratio	41.81
Forward PE	19.95
Dividend	$0.28 (0.28%)
Ex-Dividend Date	Jul 18, 2025

Volume	1,138,613
Open	100.37
Previous Close	101.50
Day's Range	98.31 - 101.36
52-Week Range	87.70 - 129.50
Beta	0.98
Analysts	Buy
Price Target	123.29 (+25.13%)
Earnings Date	Jul 28, 2025

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for tes...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1937
• Employees: 11,000
• Stock Exchange: NYSE
• Ticker Symbol: RVTY
• Website: https://www.revvity.com

Financial Performance

In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.

Analyst Summary

According to 14 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $123.29, which is an increase of 25.13% from the latest price.

Price Target

$123.29

(25.13% upside)

Analyst Consensus: Buy